Quantcast

Latest Biologic Stories

2014-05-08 08:31:53

ROCKVILLE, Md., May 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. The Company's extensive C. diff patent estate...

2014-05-06 04:23:34

SEATTLE, May 6, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics'...

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...

2014-05-05 08:28:08

SHANGHAI and TAIPEI, May 5, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX) and TaiMed Biologics today announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi's biologics facilities for ongoing treatment of patients under investigator-sponsored IND's. This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which marks an important...

2014-05-05 00:21:27

COVA322 is First of Covagen's Bispecific FynomAbs to Enter Clinical Trials ZURICH-SCHLIEREN, Switzerland, May 5, 2014 /PRNewswire/ -- Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb® developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39 patients with psoriasis and evaluate safety as well as...

2014-05-02 23:00:27

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html). (PRWEB) May 03, 2014 Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast...

2014-04-30 08:33:09

Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies. Conditionally active antibodies are...

2014-04-30 08:31:49

-- Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET-- ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta(TM) (oral estriol), which the Company is developing as a once-daily adjunctive...

2014-04-29 23:22:06

Gallus BioPharmaceuticals, a premier pure-play biologics contract development and manufacturing organization and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT), jointly announced finalization of a multi-stage manufacturing services agreement. St. Louis, Missouri (PRWEB) April 29, 2014 Gallus BioPharmaceuticals, LLC(Gallus), a premier pure-play biologics contract development and manufacturing...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.